Today: 10 November 2025
Subscribe
Browse Category

NYSE:LLY News 10 September 2025 - 17 October 2025

Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk’s Weight-Loss Crown at Risk? NVO Stock Slumps Amid Surprise Deals – What’s Next

NVO Stock Slides as Weight-Loss Hype Cools Novo Nordisk’s stock has been on a wild ride. After becoming Europe’s most valuable company in 2022–2023 on the back of its smash-hit obesity drug Wegovy, the Danish pharma giant has seen its fortunes reverse sharply in 2025. As of October 17, NVO shares trade in the mid-$50s – down nearly 50% from January levels reuters.com reuters.com and miles below the late-2024 peak (when Novo’s market cap neared $650 B) reuters.com reuters.com. What happened? In short, the once-unbounded GLP-1 weight-loss boom has hit reality. Several factors have converged to deflate Novo’s valuation. Competition has
17 October 2025
 ·  ·  ·  ·  ·  ·  ·  · 
Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer Stock Soars After Trump’s Drug Deal and Obesity Bet – Is This the Start of a Comeback?

Stock Performance: From Laggard to Late-September Lift For much of 2025, Pfizer’s stock was stuck in a rut – but that changed dramatically as Q4 approached. By late September, PFE had drifted down near multi-year lows around $23, reflecting a post-pandemic hangover. As of Sept 25, the stock was down roughly 9% year-to-date and about 18% below its level one year prior ts2.tech. It traded near the bottom of its 52-week range ($20.92 – $30.43), weighed down by steep declines in COVID vaccine and pill sales and general pessimism on its growth prospects ts2.tech ts2.tech. In fact, Pfizer’s COVID-driven revenues
6 October 2025
 ·  ·  ·  ·  ·  ·  · 
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly Stock Rockets on GLP‑1 Boom and New Approvals: Is LLY the Next Trillion‑Dollar Pharma Titan?

In‑Depth Report Introduction Eli Lilly and Company (NYSE: LLY) has become the poster‑child for the emerging class of GLP‑1‑based obesity and diabetes therapies. Its injectable tirzepatide products Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management) have delivered explosive growth, propelling the company’s market capitalization into the high‑hundred‑billion range. On 6 Oct 2025, LLY traded around $840, close to its all‑time highs marketbeat.com. The company’s pivot toward metabolic and neurodegenerative diseases, combined with an aggressive manufacturing expansion, has made it one of the most closely watched stocks on Wall Street. Stock Performance and Valuation After an extraordinary rally in late September 2025, LLY opened
6 October 2025
 ·  ·  ·  ·  · 
Bitcoin Blasts Past $125K, AI Wars Escalate, and Space Tech Soars – Global Tech Roundup (Oct 5–6, 2025)

Bitcoin Blasts Past $125K, AI Wars Escalate, and Space Tech Soars – Global Tech Roundup (Oct 5–6, 2025)

Artificial Intelligence (AI) OpenAI vs. Musk’s xAI – legal battle heats up: The Silicon Valley rivalry between Elon Musk and OpenAI turned into open warfare in court. Musk’s AI startup xAI sued OpenAI, accusing it of poaching staff to steal trade secrets related to xAI’s Grok chatbot. This week OpenAI hit back, asking a judge to dismiss the suit and blasting it as part of Musk’s “ongoing harassment” of the company reuters.com. OpenAI’s filing argued that “talented xAI employees are leaving in droves” under Musk and have every right to join OpenAI reuters.com. Musk, a co-founder turned critic of OpenAI,
6 October 2025
 ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  · 
U.S. Stocks Rally as Shutdown Fears Fade – Markets Hit Fresh Records

U.S. Stocks Rally as Shutdown Fears Fade – Markets Hit Fresh Records

Market commentary and outlook Lara Castleton of Janus Henderson noted that Tuesday’s White House–Pfizer announcement “was the catalyst for healthcare,” freeing up investors to rotate into the beaten-down sector reuters.com. Kyle Rodda at Capital.com observed that the weak ADP report “suggests the U.S. economy is in almost dire need for further policy support,” so markets are pricing in much higher odds of Fed rate cuts in October and December reuters.com. He added that “after some initial jitters, markets shrugged off the U.S. government shutdown, at least for now,” since past shutdowns have had “trivial” market impact reuters.com. Analysts are watching
2 October 2025
 ·  ·  ·  ·  ·  ·  ·  ·  ·  · 
Market Record Rally Amid Shutdown: A Deep Dive into U.S. Stock Performance on 1 October 2025

Market Record Rally Amid Shutdown: A Deep Dive into U.S. Stock Performance on 1 October 2025

Market Overview Index Performance The 1 October 2025 session began under a cloud as the federal government shut down due to a budget impasse. Stock futures opened lower amid fears that key economic reports might be delayed investopedia.com. By the closing bell, however, Wall Street had staged a dramatic recovery: Contrary to midday reports that the S&P 500 and Nasdaq 100 were modestly negative due to a risk‑off mood nasdaq.com, late‑day buying pushed all major indices into positive territory. Market breadth improved: the S&P 500 recorded 37 new 52‑week highs versus 7 lows, while the Nasdaq tallied 111 highs and 68 lows reuters.com. Sector
1 October 2025
 ·  ·  ·  ·  ·  ·  ·  ·  · 
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly Stock Surges on Obesity-Drug Boom – Is $1,000 Next?

Stock Market Performance In early October 2025, Eli Lilly (NYSE: LLY) stock leapt upward. After closing around $726 on Sept. 29 and ~$763 on Sept. 30 nasdaq.com, it spiked to about $832 intraday on Oct. 1. Trading volumes were well above average on that run. Financial media noted a flurry of bullish option trades and news-driven optimism: a major study found that GLP-1 weight-loss drugs (like Lilly’s Mounjaro) may significantly reduce Alzheimer’s risk fiercepharma.com, feeding excitement about Lilly’s broad pipeline. Tip-rank and investing sites attributed the rally to strong earnings, insider buying, and renewed interest in Lilly’s obesity/Alzheimer’s franchise tipranks.com fiercepharma.com. Overall, LLY’s
1 October 2025
 ·  ·  ·  ·  · 
Wall Street Rebound: Fed Relief, Tariff Twists & Tech Surprises (NYSE Highlights Sept 26–27, 2025)

Wall Street Rebound: Fed Relief, Tariff Twists & Tech Surprises (NYSE Highlights Sept 26–27, 2025)

Key Facts Market Recap & Broad Trends Flags and tickers on the NYSE trading floor in New York City, reflecting a week of shifting market sentiment. U.S. stocks rallied into the weekend after overcoming mid-week losses reuters.com reuters.com. Wall Street finished the week with a relief rally, snapping a multi-session losing streak. On Friday, Sept. 26, the Dow Jones Industrial Average jumped about 300 points (+0.7%) to 46,247, the S&P 500 gained +0.6% to 6,644, and the Nasdaq Composite rose +0.4% to 22,484 reuters.com. This rebound followed three straight down sessions through Thursday, which had left the major indexes in
27 September 2025
 ·  ·  ·  ·  ·  ·  ·  ·  · 
Wall Street Rebounds: PCE In‑Line, Tariff Shock, and Fed‑Cut Bets — What It All Means (Sept. 26, 2025)

Wall Street Rebounds: PCE In‑Line, Tariff Shock, and Fed‑Cut Bets — What It All Means (Sept. 26, 2025)

Key facts (today) The U.S. stock market today — what moved prices 1) The data that mattered: PCE & spendingMarkets exhaled as the Fed’s preferred inflation gauge arrived exactly as expected: headline PCE +0.3% m/m (2.7% y/y), core +0.2% m/m (2.9% y/y). Treasury yields drifted lower, with the 10‑yr near 4.18% and the 2‑yr around 3.65%, signaling relief that there was no upside shock. Futures ticked higher on the print.  Reuters “This should give some reassurances on the inflation side,” said Doug Beath of Wells Fargo Investment Institute.  Reuters Consumer spending stayed solid in August, adding to this week’s Q2 GDP revision to 3.8%. The resilience complicates the Fed’s job (growth strong, inflation easing
26 September 2025
 ·  ·  ·  ·  ·  ·  ·  ·  ·  · 
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly’s Weight-Loss Pill Sheds Pounds Fast—But Hits a Plateau: What New Trial Results Mean for the Obesity Drug Race

Trial Results: Big Early Losses, Then Weight Loss Levels Off This highly anticipated trial put Lilly’s oral GLP-1 drug, orforglipron, to the test in a large group of adults struggling with obesity. The study enrolled 3,127 overweight or obese participants (none had diabetes, but all had weight-related health issues) and randomly assigned them to various daily doses of the pill or a placebo for 72 weeks reuters.com. The outcomes were encouraging yet mixed. Patients on the highest dose (36 mg daily) lost on average about 11–12% of their starting body weight by week 72 theguardian.com. In practical terms, that’s roughly
17 September 2025
 ·  ·  ·  ·  ·  · 
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Richmond’s New Pharma Giant: Overview of Lilly’s $5B Factory Eli Lilly’s forthcoming Richmond-area factory is set to be one of the largest and most advanced pharmaceutical manufacturing sites in the world. At a cost of $5 billion, Lilly will construct a high-tech production campus in Goochland County’s West Creek Business Park, a site that had been prepped for a previous project and now deemed “the perfect spot” for fast construction washingtonpost.com. The facility’s core mission: make more of the critical drug ingredients that Lilly usually sources overseas, right here on U.S. soil washingtonpost.com washingtonpost.com. Scale and Scope: The plant will
16 September 2025
 ·  ·  ·  ·  ·  ·  ·  ·  · 
Game-Changing AI Breakthroughs, Big Tech Surprises & Global AI Showdowns (Sept 9–10, 2025)

Game-Changing AI Breakthroughs, Big Tech Surprises & Global AI Showdowns (Sept 9–10, 2025)

Breakthrough: AI Finds Consciousness in ‘Unresponsive’ Patients One of the week’s most striking research breakthroughs came from Stony Brook University, where scientists unveiled an AI system called SeeMe that can detect “covert consciousness” in patients with acute brain injuries news.stonybrook.edu. In a study of 37 coma patients, SeeMe’s computer vision algorithms analyzed subtle, involuntary facial muscle movements in response to verbal commands (like “open your eyes”), movements so slight they’re invisible to the naked eye news.stonybrook.edu. Remarkably, the tool identified signs of awareness 4–8 days earlier than standard bedside neurological exams news.stonybrook.edu news.stonybrook.edu. Lead researcher Dr. Sima Mofakham explained the
10 September 2025
 ·  ·  ·  ·  ·  ·  ·  · 
1 2 3
Go toTop